Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 10Recruiting 9Completed 6Not yet recruiting 5Active not recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 425Neoplasms 284Carcinoma, Non-Small-Cell Lung 274Colorectal Neoplasms 236Prostatic Neoplasms 173Lung Neoplasms 171Carcinoma, Hepatocellular 157Stomach Neoplasms 126Leukemia, Myeloid, Acute 120Pancreatic Neoplasms 118Multiple Myeloma 106Recurrence 100Uterine Cervical Neoplasms 97Squamous Cell Carcinoma of Head and Neck 89Neoplasm Metastasis 88Rectal Neoplasms 87Ovarian Neoplasms 81Triple Negative Breast Neoplasms 78Small Cell Lung Carcinoma 72Head and Neck Neoplasms 70Brain Neoplasms 70Glioblastoma 65Esophageal Neoplasms 65Endometrial Neoplasms 59Colonic Neoplasms 59Melanoma 56Hematologic Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Motor Activity 48Glioma 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Advanced Malignant Tumors × Clear all
NCT07409766 2026-02-13

A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase EARLY_PHASE1 Not yet recruiting
20 enrolled

Advanced Malignant Tumors

NCT07338838 2026-01-14

To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled

Advanced Malignant Tumors

NCT06770881 2025-01-13

JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Not yet recruiting
430 enrolled

Advanced Malignant Tumors

NCT06691360 2024-11-15

AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

Akeso

Phase 1 Not yet recruiting
87 enrolled

Advanced Malignant Tumors

NCT06226363 2024-01-26

Phase I Study of LNF1901 in Advanced Malignant Tumors

Shandong New Time Pharmaceutical Co., LTD

Phase 1 Not yet recruiting
82 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡